[HTML][HTML] Nanotechnology-based strategies against SARS-CoV-2 variants
Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) has already infected more
than 500 million people globally (as of May 2022), creating the coronavirus disease 2019 …
than 500 million people globally (as of May 2022), creating the coronavirus disease 2019 …
SARS-CoV-2 antiviral therapy
The development of effective antiviral therapy for COVID-19 is critical for those awaiting
vaccination, as well as for those who do not respond robustly to vaccination. This review …
vaccination, as well as for those who do not respond robustly to vaccination. This review …
Shifting mutational constraints in the SARS-CoV-2 receptor-binding domain during viral evolution
Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) has evolved variants with
substitutions in the spike receptor-binding domain (RBD) that affect its affinity for angiotensin …
substitutions in the spike receptor-binding domain (RBD) that affect its affinity for angiotensin …
[HTML][HTML] Assessing transmissibility of SARS-CoV-2 lineage B. 1.1. 7 in England
Abstract The SARS-CoV-2 lineage B. 1.1. 7, designated variant of concern (VOC) 202012/01
by Public Health England, was first identified in the UK in late summer to early autumn 2020 …
by Public Health England, was first identified in the UK in late summer to early autumn 2020 …
mRNA vaccination boosts cross-variant neutralizing antibodies elicited by SARS-CoV-2 infection
L Stamatatos, J Czartoski, YH Wan, LJ Homad, V Rubin… - Science, 2021 - science.org
Emerging severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) variants have
raised concerns about resistance to neutralizing antibodies elicited by previous infection or …
raised concerns about resistance to neutralizing antibodies elicited by previous infection or …
Transmission of SARS-CoV-2 Lineage B. 1.1. 7 in England: Insights from linking epidemiological and genetic data
Abstract The SARS-CoV-2 lineage B. 1.1. 7, now designated Variant of Concern 202012/01
(VOC) by Public Health England, originated in the UK in late Summer to early Autumn 2020 …
(VOC) by Public Health England, originated in the UK in late Summer to early Autumn 2020 …
[HTML][HTML] Deep mutational scans for ACE2 binding, RBD expression, and antibody escape in the SARS-CoV-2 Omicron BA. 1 and BA. 2 receptor-binding domains
SARS-CoV-2 continues to acquire mutations in the spike receptor-binding domain (RBD)
that impact ACE2 receptor binding, folding stability, and antibody recognition. Deep …
that impact ACE2 receptor binding, folding stability, and antibody recognition. Deep …
[HTML][HTML] Analysis of SARS-CoV-2 variant mutations reveals neutralization escape mechanisms and the ability to use ACE2 receptors from additional species
Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) variants continue to
emerge during the global pandemic and may facilitate escape from current antibody …
emerge during the global pandemic and may facilitate escape from current antibody …
[HTML][HTML] A single dose of the SARS-CoV-2 vaccine BNT162b2 elicits Fc-mediated antibody effector functions and T cell responses
A Tauzin, M Nayrac, M Benlarbi, SY Gong, R Gasser… - Cell host & …, 2021 - cell.com
While the standard regimen of the BNT162b2 mRNA vaccine for SARS-CoV-2 includes two
doses administered 3 weeks apart, some public health authorities are spacing these doses …
doses administered 3 weeks apart, some public health authorities are spacing these doses …
[HTML][HTML] Neutralization of N501Y mutant SARS-CoV-2 by BNT162b2 vaccine-elicited sera
Rapidly spreading variants of SARS-CoV-2 that have arisen in the United Kingdom and
South Africa share the spike N501Y substitution, which is of particular concern because it is …
South Africa share the spike N501Y substitution, which is of particular concern because it is …